Company profile
Akanda Corp.
NASDAQ: AKAN · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONCIK 0001888014Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 20
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ filing timeliness, listing tenure
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
-77.1%
Net income (FY)
-$4.1M
Employees
8
as of 2026-08-18
Market cap
$162.2k
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$4.1M-$4.1M2024
Total assets$7.9M$7.9M2024
Liabilities$3.6M$3.6M2024
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Akanda Corp.’s financial profile?
Akanda Corp. earned -$4.1M in FY2024 net income.
Peers · Healthcare
SFLMaven Corp.——Fifty 1 Labs, Inc.——Garrison Film Productions Inc.——BioLife Sciences Inc.——Rimrock Gold Corp.——GelStat Corporation——Key facts
CEOKatharyn Field
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeNASDAQ: AKAN
Employees8
IPO date2022-03-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.